WuXi Biologics , a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award." The Life Sciences Industry Awards are among Ireland's foremost industry recognition programs, celebrating excellence, innovation, and leadership across the country's pharmaceutical, biotechnology, medical device, and broader life sciences sectors.
The company was shortlisted across eight award categories, reflecting the breadth of capabilities and achievements demonstrated by its Ireland site. Among the honors received, WuXi Biologics' Manufacturing Science & Technology (MSAT) Team was named Life Sciences Team of the Year and subsequently selected for the Overall Excellence in Life Sciences award, recognizing the team's exceptional contributions to advancing manufacturing science, technology transfer, operational performance, and delivery excellence.
These latest honors build upon a series of major milestones achieved by the Ireland site in recent years, including HPRA GMP authorization and EMA approval for commercial manufacturing of innovative biologic products. Since commencing operations, the WuXi Biologics Ireland site has established itself as one of Europe's most advanced single-use biologics manufacturing facilities, earning international recognition for its operational excellence, innovation, and sustainability performance.
Other accolades the Ireland site has received include the ISPE Facility of the Year Award and the Operational Excellence in Life Sciences Award. All together, these achievements underscore the site's growing role in supporting global biologics development and commercial manufacturing while contributing to the continued advancement of Ireland's thriving life sciences ecosystem.